Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Intellia Therapeutics (NTLA) Receivables - Other (2016 - 2023)

Intellia Therapeutics (NTLA) has disclosed Receivables - Other for 9 consecutive years, with $1.0 million as the latest value for Q4 2023.

  • On a quarterly basis, Receivables - Other fell 37.5% to $1.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.0 million, a 37.5% decrease, with the full-year FY2023 number at $1.0 million, down 37.5% from a year prior.
  • Receivables - Other was $1.0 million for Q4 2023 at Intellia Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $8.4 million in Q1 2020 to a low of $100000.0 in Q4 2021.
  • A 5-year average of $1.7 million and a median of $1.0 million in 2019 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: crashed 88.1% in 2021, then soared 1500.0% in 2022.
  • Intellia Therapeutics' Receivables - Other stood at $3.6 million in 2019, then plummeted by 66.67% to $1.2 million in 2020, then plummeted by 91.67% to $100000.0 in 2021, then skyrocketed by 1500.0% to $1.6 million in 2022, then tumbled by 37.5% to $1.0 million in 2023.
  • Per Business Quant, the three most recent readings for NTLA's Receivables - Other are $1.0 million (Q4 2023), $1.0 million (Q3 2023), and $1.4 million (Q2 2023).